Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries-Reference-Cited by-同舟云学术

Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Bhatta Pallavi¹,Whale Kevin D.²,Sawtell Amy K.²,Thompson Clare L.³,Rapecki Stephen E.¹,Cook David A.²,Twomey Breda M.²,Mennecozzi Milena²,Starkie Laura E.¹,Barry Emily M. C.¹,Peters Shirley J.¹,Kamal Ahmad M.⁴,Finney Helene M.²

Affiliation:

1. New Modalities and Therapeutics Group, UCB Pharma, Slough, Berkshire UK

2. In Vitro Pharmacology Group, UCB Pharma, Slough, Berkshire, UK

3. Immunology Research Group, UCB Pharma, Slough, Berkshire UK

4. Immunology Partnering Group, UCB Pharma, Slough, Berkshire UK

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1859049

Reference54 articles.

1. Antibodies to watch in 2020

2. The making of bispecific antibodies

3. Bispecific Antibody Therapy in Hemophilia

4. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

5. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates;Bioresources and Bioprocessing;2024-08-23

2. Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows;mAbs;2024-02-21

3. A Generic Approach for Miniaturized Unbiased High-Throughput Screens of Bispecific Antibodies and Biparatopic Antibody–Drug Conjugates;International Journal of Molecular Sciences;2024-02-08

4. ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies;Molecular Cancer Therapeutics;2024-02-07

5. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET;mAbs;2024-01-12